Evaluation of the specificity of the 2023 European Society of Cardiology classification for infective endocarditis.

2023 ESC criteria Diagnostic tools Infective endocarditis Specificity

Journal

Infectious diseases (London, England)
ISSN: 2374-4243
Titre abrégé: Infect Dis (Lond)
Pays: England
ID NLM: 101650235

Informations de publication

Date de publication:
09 Oct 2024
Historique:
medline: 9 10 2024
pubmed: 9 10 2024
entrez: 9 10 2024
Statut: aheadofprint

Résumé

The 2023 Duke-ISCVID and 2023 ESC classifications have recently issued independent diagnostic criteria for infective endocarditis (IE), updating the 2015 ESC criteria. The specificity of the 2023 ESC criteria should be evaluated and compared to the two other classifications in IE suspected patients. We retrospectively collected the characteristics of patients hospitalised in Bichat University Hospital, in 2021, who had been evaluated for suspicion of IE, and in whom IE diagnosis was finally rejected. All were classified by 2015 ESC, 2023 Duke-ISCVID, and 2023 ESC. In total 130 patients were analysed. Mean age was 62 years, 64.6% were male, 30.0% had prosthetic cardiac valve or valve repair, 16.2% had cardiac implanted electronic device, and 23.1% other cardiac conditions. Overall, 2, 5 and 5 patients were falsely classified as definite IE with the 2015 ESC, 2023 Duke-ISCVID and 2023 ESC criteria, respectively. The corresponding specificities were 99% (95% CI [94%; 100%], 96% (95% CI [91%; 99%]), and 96% (95% CI [91%; 99%]). The 2023 ESC and the 2023 Duke-ISCVID criteria are highly specific, although slightly less than the 2015 ESC criteria, for ruling out the diagnosis of definite IE.HIGHLIGHTS2023 Duke-ISCVID and 2023 ESC criteria are recently issued diagnostic classifications2023 ESC criteria have an excellent specificity, equivalent to the 2023 Duke-ISCVID one2023 ESC criteria and the 2023 Duke-ISCVID are less specific than the 2015 ESC criteriaSpecificities were quite similar according to the nature of the cardiac valve (native or prosthetic valve) or the duration of antibiotic therapy.

Sections du résumé

BACKGROUND UNASSIGNED
The 2023 Duke-ISCVID and 2023 ESC classifications have recently issued independent diagnostic criteria for infective endocarditis (IE), updating the 2015 ESC criteria.
OBJECTIVES UNASSIGNED
The specificity of the 2023 ESC criteria should be evaluated and compared to the two other classifications in IE suspected patients.
METHODS UNASSIGNED
We retrospectively collected the characteristics of patients hospitalised in Bichat University Hospital, in 2021, who had been evaluated for suspicion of IE, and in whom IE diagnosis was finally rejected. All were classified by 2015 ESC, 2023 Duke-ISCVID, and 2023 ESC.
RESULTS UNASSIGNED
In total 130 patients were analysed. Mean age was 62 years, 64.6% were male, 30.0% had prosthetic cardiac valve or valve repair, 16.2% had cardiac implanted electronic device, and 23.1% other cardiac conditions. Overall, 2, 5 and 5 patients were falsely classified as definite IE with the 2015 ESC, 2023 Duke-ISCVID and 2023 ESC criteria, respectively. The corresponding specificities were 99% (95% CI [94%; 100%], 96% (95% CI [91%; 99%]), and 96% (95% CI [91%; 99%]).
CONCLUSION UNASSIGNED
The 2023 ESC and the 2023 Duke-ISCVID criteria are highly specific, although slightly less than the 2015 ESC criteria, for ruling out the diagnosis of definite IE.HIGHLIGHTS2023 Duke-ISCVID and 2023 ESC criteria are recently issued diagnostic classifications2023 ESC criteria have an excellent specificity, equivalent to the 2023 Duke-ISCVID one2023 ESC criteria and the 2023 Duke-ISCVID are less specific than the 2015 ESC criteriaSpecificities were quite similar according to the nature of the cardiac valve (native or prosthetic valve) or the duration of antibiotic therapy.

Identifiants

pubmed: 39382991
doi: 10.1080/23744235.2024.2412155
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-5

Auteurs

Hugo Moisset (H)

Infectious Diseases Department, Bichat-Claude Bernard University Hospital, Paris, France.
Paris Cité University, Paris, France.

Julien Rio (J)

Paris Cité University, Paris, France.
Center of Clinical Investigations, Bichat-Claude Bernard University Hospital, AP-HP, Paris, France.
Inserm CIC 1425, Paris, France.

Gaspard Suc (G)

Cardiology Department, Bichat-Claude Bernard University Hospital, AP-HP, LVTS U1148, Université Paris-Cité, Paris, France.

Johan Benhard (J)

Infectious Diseases Department, Bichat-Claude Bernard University Hospital, Paris, France.
Paris Cité University, Paris, France.

Florence Arnoult (F)

Department of Physiology, Bichat-Claude Bernard University Hospital, AP-HP, Paris, France.

Laurene Deconinck (L)

Infectious Diseases Department, Bichat-Claude Bernard University Hospital, Paris, France.

Nathalie Grall (N)

Microbiology Laboratory, Bichat-Claude Bernard University Hospital, AP-HP, Paris, France.
Inserm, UMR-1137, IAME, Paris, France.

Bernard Iung (B)

Paris Cité University, Paris, France.
Cardiology Department, Bichat-Claude Bernard University Hospital, AP-HP, LVTS U1148, Université Paris-Cité, Paris, France.

Francois-Xavier Lescure (FX)

Infectious Diseases Department, Bichat-Claude Bernard University Hospital, Paris, France.
Paris Cité University, Paris, France.
Inserm, UMR-1137, IAME, Paris, France.

François Rouzet (F)

Paris Cité University, Paris, France.
Nuclear Medicine Department, Bichat-Claude Bernard University Hospital, Paris, France.
Inserm U1148, Laboratory for Vascular Translational Science, Bobigny Cedex, France.

Bruno Hoen (B)

Université de Lorraine, Nancy Cedex, France.

Xavier Duval (X)

Paris Cité University, Paris, France.
Center of Clinical Investigations, Bichat-Claude Bernard University Hospital, AP-HP, Paris, France.
Inserm CIC 1425, Paris, France.
Inserm, UMR-1137, IAME, Paris, France.

Claire Amaris Hobson (CA)

Infectious Diseases Department, Bichat-Claude Bernard University Hospital, Paris, France.
Paris Cité University, Paris, France.

Classifications MeSH